FairJourney Biologics has appointed Marc van Dijk as the new Chief Scientific Officer of Antibody Discovery and Engineering
FairJourney Biologics recently appointed Marc van Dijk as the new Chief Scientific Officer of Antibody Discovery and Engineering.
Marc van Dijk is an experienced biotechnology executive with over 30 years in molecular biology and immuno-oncology.
He is currently the Chief Scientific Officer for Discovery and Engineering at FairJourney Biologics, where he leads efforts in biologics discovery and engineering.
Before joining FairJourney, Marc served as the Chief Scientific Officer at MiNK Therapeutics from 2022 to 2024, where he spearheaded research into NK cell-based therapies for cancer.
His leadership helped advance novel immunotherapies aimed at enhancing the immune system’s ability to target and eliminate cancer cells.
Marc also held key positions at Agenus Inc., including Chief Technology Officer (2020–2022) and Executive Director, Platform Technology & Site Head at Agenus UK (2017–2020).
At Agenus, he played a pivotal role in the development of engineered T cell receptors (TCRs) and chimeric antigen receptors (CARs) for cancer immunotherapy.
He also led receptor discovery efforts at AgenTus Therapeutics, a subsidiary of Agenus, focusing on cutting-edge adoptive cell therapies.
Marc earned a Ph.D. in Molecular Biology from Utrecht University in 1992 and completed postdoctoral research at UC San Diego. He is recognized for his expertise in immune-oncology, biologics, and cell-based therapies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023